amiodarone has been researched along with Vertigo in 2 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Vertigo: An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Paraesthesiae, ataxia, vertigo and tremor were the most common (7-9%)." | 1.28 | Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme. ( Coulter, DM; Edwards, IR; Savage, RL, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arbusow, V | 1 |
| Strupp, M | 1 |
| Brandt, T | 1 |
| Coulter, DM | 1 |
| Edwards, IR | 1 |
| Savage, RL | 1 |
2 other studies available for amiodarone and Vertigo
| Article | Year |
|---|---|
Amiodarone-induced severe prolonged head-positional vertigo and vomiting.
Topics: Aged; Amiodarone; Humans; Male; Posture; Vertigo; Vestibular Diseases; Vomiting | 1998 |
Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme.
Topics: Amiodarone; Ataxia; Humans; Nervous System Diseases; New Zealand; Paresthesia; Product Surveillance, | 1990 |